Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
10/18/19
1
Golden Nuggets: Bugs, Drugs and Antibiotic Stewardship
Please logon to: www.ascp.com/qa and find the session title to submit your questions.
1
Pharmacist Learning Objectives • Discuss methods for prevention, treatment of infection with best in
class/new therapies, and prevention of drug resistance for use in the older adult.• Identify novel strategies for therapeutics for infectious conditions
and antibiotic stewardship.• Describe medication strategies for prevention of bacterial resistance
and best practices in antibiotic stewardship.• List practice models for antibiotic stewardship and prevention of drug
resistance in senior care practice settings.
2
10/18/19
2
Pharmacy Technician Learning Objectives• List best in class and new therapies for use in the
older adult.• Identify novel therapeutic strategies for infectious
conditions.•Describe best practices in antibiotic stewardship for
older adults.
3
Chair and Moderator
• Dr. Deborah Milito
• Disclosure: I have no actual or potential conflict of interest to this presentation. I have no financial relationships with regard to this presentation to disclose.
4
10/18/19
3
Topics and Speakers (Each talk is 15 minutes)1. Bugs & Drugs for the Older Adult—Spencer Durham2. AnNbioNc Adverse Drug Events: Improving PaNent Assessment and Management—Joshua
Chou3. New and Future AnNbioNcs in the Pipeline—Jonathan Cho
15 minute Q&A Session with first 3 speakers
4. OpNmizing The Use Of Clinical Laboratory Values In AnNmicrobial Stewardship—Nicholas Ladikos
5. Clostridioides difficile InfecNon in the Older Adult—Elias B. Chahine6. MulN-Drug Resistant Organisms—Eddie Grace
15 minute Q&A Session with second 3 speakers
5
Bugs & Drugs for the
Older AdultSpencer H. Durham, Pharm.D., BCPS, BCIDP
Associate Clinical Professor of Pharmacy PracticeDirector, Alumni & Professional Affairs
Auburn University Harrison School of Pharmacy
6
10/18/19
4
Disclosure
I have no conflicts of interest to disclose.
7
Introduction
• “The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism. I hope this evil can be averted.”
- Sir Alexander Fleming
8
10/18/19
5
Introduction
• Multidrug-resistant organisms (MDROs) are increasing at an alarming rate• 2 million illnesses and 23,000 deaths associated with antibiotic-resistant
bacteria annually• Misuse of antimicrobial agents is the major contributing factor to
disseminated resistance• Up to 50% of antimicrobials prescribed in the outpatient, emergency, and
acute care settings are unnecessary or inappropriate• Up to 75% of antimicrobials in the long-term care setting are prescribed
inappropriately
9
Introduction
• Older adults are at a high risk of infection with MDROs• Immune system naturally weakens over time
• Immunosenescence
• Have likely been exposed to many courses of antibiotics over time• Comorbidities may predispose to acquiring certain infections
• Examples: diabetes, COPD
• May be at higher risk for adverse effects associated with antimicrobial treatment• C.difficile infection
10
10/18/19
6
Introduction
• Antimicrobial therapy crosses into most, if not all, areas of pharmacy practice• Many antibiotics are either unnecessary, or prescribed
inappropriately, all of which may contribute to antimicrobial resistance• No indication for antibiotic therapy• Incorrect antibiotic for the disease• Incorrect dose, frequency or duration
• Limited development of new antibiotics, particularly novel antibiotics
11
Goals of Antimicrobial Therapy
• In general, ultimate goal is to eradicate the causative organism of infection• Treat infection appropriately
• Empiric therapy: target most likely pathogens for the disease state• Definitive therapy: use the least broad-spectrum, yet most appropriate,
therapy to target the known pathogen
• Minimize the development of antimicrobial resistance• Use most narrow-spectrum, effective agent possible• Judicious overall use of antimicrobials
• Example: Abx use for infections likely due to viral causes
12
10/18/19
7
Antimicrobial Considerations
• Empiric therapy• Broad-spectrum agent(s) with reliable coverage against the most likely
causative pathogens
• Definitive therapy• Can generally only be done after obtaining culture and sensitivity results• May use other tests to guide therapy, such as PCRs
• Duration of treatment• Not well-defined, usually based on experience rather than evidence• Generally, 7-14 days for most infections
13
Antimicrobial Stewardship
• SNAP approach to antimicrobial stewardship• Safety, Need, Adequacy, Prudence• Step-by-step process to assess antimicrobial therapy when antibiotics
have already been prescribed• If initially recommending an antibiotic, change to the NAPS approach
14
10/18/19
8
Antimicrobial Stewardship
• “S” – Safety• Ask “is it safe for this patient to be receiving this antimicrobial?”• Assessment of allergies• Assess for likelihood of potential adverse drug reactions
15
Antimicrobial Stewardship
• “N” – Need• Ask “Does this paNent need anNmicrobial therapy?
• Does the paNent actually have an infecNon?• Is the infecNon likely to be:
• Bacterial?• Viral?• Fungal?
16
10/18/19
9
Antimicrobial Stewardship
• “A” – Adequacy• Ask “Is the prescribed antimicrobial treating, or likely to treat, the
infection?”• Is the antimicrobial a guideline recommended therapy?• Does the antimicrobial provide appropriate coverage against the pathogens
most likely causing the infection?• Will the antimicrobial reach the site of infection?
17
Antimicrobial Stewardship
• “P” – Prudence• Ask “Is this the most prudent drug to use for this infection?”
• Is the drug the most-narrow spectrum agent that will adequately treat this infection?
• This often cannot be fully assessed unless culture and susceptibility results are available
18
10/18/19
10
Self-Assessment Question #1
• D.B. is a 67-year-old male, permanent resident of a LTCF, who is admitted to the hospital for evaluation of difficulty breathing, 3 day history of fever, productive cough, night sweats, and chills• Allergies: NKDA• PMH: T2DM, HTN, dyslipidemia• Meds: Metformin, glypizide, atorvastatin, lisinopril, HCTZ• PE: BP-130/82; HR-90; RR-28; Temp 103.5°F• Chest x-ray reveals bilateral infiltrates
19
Self-Assessment Question #1
What is the best recommendation for D.B. at this time?A. Begin oral azithromycin 500 mg PO on day 1, then 250 mg on days
2-5B. Do not begin antibiotics, infection is likely viral; supportive care
onlyC. Begin ciprofloxacin 500 mg IV BIDD. Begin ceftriaxone 2 grams IV once daily plus azithromycin 500 mg
IV once daily
20
10/18/19
11
Self-Assessment Question #1
What is the best recommendation for D.B. at this time?A. Begin oral azithromycin 500 mg PO on day 1, then 250 mg on days
2-5B. Do not begin antibiotics, infection is likely viral; supportive care
onlyC. Begin ciprofloxacin 500 mg IV BIDD. Begin ceftriaxone 2 grams IV once daily plus azithromycin 500 mg
IV once daily
21
References
• Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62(10):1197-202.
• Cunha CB, Cunha BA. Antibiotic essentials. 15 ed. London, England: JaypeeBrothers Medical Publishing; 2017.
• Gallagher JC, Macdougall C. Antibiotics simplified. 4 ed. Burlington, MA: Jones & Bartlett Learning; 2018.
• Gilbert DN, Chambers HF, Eliopoulos GM, et al. The Sanford Guide to Antimicrobial Therapy. 48 ed. Sperryville, VA: Antimicrobial Therapy, Inc; 2018.
• The core elements of antibiotic stewardship for nursing homes. Available from: https://www.cdc.gov/longtermcare/prevention/antibiotic-stewardship.html. Accessed August 25, 2019.
22
10/18/19
12
Bugs & Drugs for the
Older AdultSpencer H. Durham, Pharm.D., BCPS, BCIDP
Associate Clinical Professor of Pharmacy PracticeDirector, Alumni & Professional Affairs
Auburn University Harrison School of Pharmacy
23
Antibiotic Adverse Drug Events: Improving
Patient Assessment and Management
Joshua Chou, PharmD
Geriatric Pharmacotherapy FellowPeter Lamy Center on Drug Therapy and Aging
University of Maryland School of Pharmacy
24
10/18/19
13
Disclosure• I have no actual or potentially relevant financial relationship to
disclose and no conflict of interest in relation to this activity.
• This work was supported by a Cooperative Agreement funded by the Centers for Disease Control and Prevention in collaboration with the Maryland Department of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Centers for Disease Control and Prevention of the Department of Health and Human Services.
25
Why Focus on Antibiotic Adverse Drug Events (AADEs)?
• Protect the resident from future exposure to the AADEs• Communicate findings with other health care clinicians to avoid
future occurrences • Comply with standards of practice• Adhere to regulatory and accreditation guidance
• Centers for Disease Control (CDC) Core Principles of Antibiotic Stewardship• State Operations Manual: Appendix PP
26
10/18/19
14
Tracking: Monitoring Antibiotic Prescribing, Use, and Resistance
Does your facility monitor one or more outcomes of antibiotic use?
− Rates of C. difficile infection− Rates of antibiotic resistant
organisms− Rates of adverse drug events due
to antibiotics
Adverse events due to use of medications in skilled nursing homes accounted for nearly 40% of harms identified in a
recent report.1 Antibiotics are among the most frequently
prescribed medications in LTCFs and have a high rate of adverse
drug events.2,3
27
Antibiotic Adverse Drug Events4
20% of hospitalized adults have at least 1 adverse drug event (ADE)
Every 10 days of antibiotic therapy confers a 3% increased risk of ADE
GI (42%), Renal (24%), Blood (15%), Liver (7%), Neurologic (7%)
RATE
RISK
TYPE
28
10/18/19
15
Antibiotic ADE: GI Event4
• Diarrhea: > 3 loose stools per day; absence of laxatives
• Nausea and/or vomiting; nausea and vomiting associated with antibiotic; no other explanation
• Prevalence: 42%• Median time to
occurrence: 5 days (2 – 9)
Nausea and vomitingassociated with
antibiotic administration
Possible Gastrointestinal Adverse Event
Contact Prescriber. Evaluate whether antibiotic can be
taken with food to decrease
nausea/vomiting.
Non-infectious diarrhea,
i.e., not C. difficile PCR positive
Contact Prescriber. Obtain C. difficile PCR if not already known. Evaluate whether probiotic/ prebiotic can be
taken at least 2 hours prior to antibiotic to decrease diarrhea.
Antibiotics Implicated
Ampicillin Amoxicillin-clavulanateAmpicillin-sulbactam OxacillinPiperacillin-tazobactam CeftriaxoneCefpodoxime CefepimeTrimethoprim-Sulfamethoxazole
ErtapenemMeropenem
AzithromycinClindamycinDoxycycline
FluoroquinolonesMetronidazole
Vancomycin
29
ADE: Renal Event4
• Increase in SCr to > 1.5 times baseline; absence of precipitating renal factors (i.e. sepsis, other nephrotoxic drugs)
• Prevalence: 24%
• Median time to occurrence: 5 days (2 – 10)
Increase in SCr to > 1.5 times baseline value
Possible Renal Event
Contact Prescriber.Evaluate other possible causes
of renal impairment, i.e. sepsis, contrast dye
Antibiotics ImplicatedAminoglycosidesTrimethoprim-
SulfamethoxazoleVancomycin IV
Ampicillin-sulbactamCephalosporins
Ampicillin
30
10/18/19
16
ADE: Blood Disorder4
• Anemia (hgb < 10 g/dL); Leukopenia (WBC < 4500 cells/μL); thrombocytopenia (platelets < 150 x 103/μL; no bleeding or myelosuppressive therapy
• Prevalence: 15%• Median time to occurrence:
12 days (6 – 24)
Decrease in Hgb to < 10 g/dL; and/orDecrease in WBC to < 4,500 cells/μL;
Decrease in platelets to < 150 x 103/μLto below baseline, in absence of
bleeding or myelosuppressive therapy
Possible Blood Disorder Event
Contact Prescriber. Evaluate other possible causes of decreased blood
counts. Consider discontinuing likely-implicated antibiotic.
Most Likely Antibiotics ImplicatedAmpicillin OxacillinPiperacillin-tazobactam CefazolinCeftriaxone CefepimeMacrolides MeropenemFluoroquinolones Trimethoprim-Sulfamethoxazole
31
ADE: Cardiac Event - Arrhythmia4-5
• QTc > 440 ms in females
• QTc > 460 ms in males on two or more EKGs; absence of pre-existing arrhythmias
• Prevalence: 1%• Median time to
occurrence: 11 days (4-18)
áQTc interval by 60 msover baseline or
áto > 440 ms in males;á to > 460 ms in females
áPossible Arrhythmia
áEvaluate HR and rhythm.áIf HR > 140 or tachyarrhythmia,áHOLD ANTIBIOTIC & CONTACT
PRESCRIBER
Anti-infective ImplicatedAzithromycinCiprofloxacinErythromycinFluconazoleLevofloxacinMoxifloxacinKetoconazoleItraconazole;
Determine if other risk factors for Torsades de Pointes exist
Evaluate need for emergency
triage, and potassium and
magnesium replacement.
32
10/18/19
17
Longer Term Antibiotic ADEs – up to 90 days4
C. Difficile Infection – Infectious Diarrhea
• Prevalence: • 3.9 cases per 10,000 person
days • 4% of study patients
• Median time to occurrence: 15 days (4 – 34)
• Implicated antibiotics: 3rd generation cephalosporins, cefepime, and fluoroquinolones
Infection with Multi-drug Resistant Organisms (MDROs)
• Prevalence: • 6.1 cases per 10,000 person days• 6% of study patients
• Median time to occurrence: within 90 days
• Gram positive resistance (4.8/10,000 person days): VRE (67%)
• Gram negative resistance (1.7/10,000 person days): extended spectrum β-lactamase production
C. difficile and MDROs infections comprised 43% of all antibiotic-associated ADEs
33
Where: EHR=electronic health record
34
10/18/19
18
Self-Assessment Question
Which of the following are reasons why documenting antibiotic adverse drug events are important?
A. Avoid future exposure to the antibiotic that caused the antibiotic adverse drug event
B. Communicate findings with other healthcare professionals to reduce future occurrences
C. To increase Medicare reimbursementD. A and B
35
Self-Assessment Question
Which of the following are reasons why documenting antibiotic adverse drug events are important?
A. Avoid future exposure to the antibiotic that caused the antibiotic adverse drug event
B. Communicate findings with other healthcare professionals to reduce future occurrences
C. To increase Medicare reimbursementD. A and B
36
10/18/19
19
Golden Nuggets
• Monitoring and documenting antibiotic adverse drug events (AADEs) is critical in reducing future AADEs.• Increasing ongoing surveillance of potential and actual AADEs needs
to be integrated into workflow.• Reducing AADEs requires an interprofessional collaborative effort
championed by the pharmacy team.
37
References1. Office of the Inspector General. Adverse Events in Skilled Nursing Facilities:
National Incidence Among Medicare Beneficiaries (OEI-06-11-00370), February 2014.
2. Nicolle LE, Bentley D, Garibaldi R, et al. Antimicrobial use in long-term care facilities. Infect Control Hosp Epidemiol 2000; 21:537–45.
3. Gurwitz JH, Field TS, Avorn J et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109:87–94.
4. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. JAMA Intern Med.2017;177(9):1308–1315.
5. Woosley RL, Heise CW , Gallo T, Tate J, Woosley D and Romero KA, www.CredibleMeds.org, QTdrugs List, Accessed August 27, 2019.
38
10/18/19
20
Antibiotic Adverse Drug Events: Improving
Patient Assessment and Management
Joshua Chou, PharmD
Geriatric Pharmacotherapy FellowPeter Lamy Center on Drug Therapy and Aging
University of Maryland School of Pharmacy
39
New and Future Antibiotics in the Pipeline
Jonathan Cho, PharmD, MBA, BCIDP, BCPS
Clinical Associate ProfessorThe University of Texas at Tyler Fisch College of Pharmacy
40
10/18/19
21
Disclosure
Jonathan Cho serves on the speakers’ bureau for Allergan.
41
Antimicrobial Drug Approval
0
2
4
6
8
10
12
14
16
18
198 3-87 198 8-92 199 3-97 199 8-20 02 200 3-07 200 8-12 201 3-18
Adapted from Spellberg B, et al. Clin Infect Dis. 2011;52:S397-S428
42
10/18/19
22
Self-Assessment Question #1
Which of the following antimicrobials works against vancomycin-resistant Enterococcus sp.?
A. Meropenem/vaborbactamB. PlazomicinC. OmadacyclineD. None of the above
43
Self-Assessment Question #1
Which of the following antimicrobials works against vancomycin-resistant Enterococcus sp.?
A. Meropenem/vaborbactamB. PlazomicinC. OmadacyclineD. None of the above
44
10/18/19
23
Delafloxacin (Baxdela®)
• Studies compared delafloxacin vs. vancomycin/aztreonam (V/A)• IV delafloxacin to V/A: 78.2% vs. 80.9% in intent-to-treat (ITT) analysis• PO delafloxacin to V/A: 83.7% vs. 80.6% in ITT analysis
• Pooled safety analysis showed no association of adverse reactions seen with other fluoroquinolones
Approval Date Indications Spectrum of Activity Dosing Clinical Pearls
June 2017 ABSSSI MRSA, P. aeruginosa 450mg PO BID or300mg IV daily
- No phototoxic effects or QTc prolongation seen
O’Riordan W, et al. Clin Infect Dis. 2018 Aug 16;67(5):657-666.Pullman J, et al. J Antimicrob Chemother. 2017 Dec 1;72(12):3471-3480.Bassetti M, et al. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S233-S240.
45
Meropenem/vaborbactam (Vabomere®)
• Phase 3 study compared meropenem/vaborbactam vs. piperacillin/tazobactam with optional PO levofloxacin switch• Overall success: 98.4% vs. 94%• Microbial eradication in ITT population: 66.7% vs. 57.7%
• What about CRE? à evaluated against best available therapy • Associated with ↑ clinical cure, ↓ mortality, and ↓ nephrotoxicity
Approval Date Indications Spectrum of Activity Dosing Clinical Pearls
August 2017 cUTI ESBL, CRE 4g (2/2g) IV q8h infused over 3 hrs
- No additional benefit against A. baumannii, P. aeruginosa
Kaye KS, et al. JAMA. 2018 Feb 27;319(8):788-799.Wunderink RG, et al. Infect Dis Ther. 2018 Dec;7(4):439-455.
46
10/18/19
24
Plazomicin (ZemdriTM)
• Phase 3 study compared plazomicin vs. meropenem• Composite cure rate at day 5: 88% vs. 91.4% • Composite cure rate at test-of-cure (TOC): 81.7% vs. 70.1% • Fewer recurrence: 3.7% vs. 8.1%• Fewer clinical relapse: 1.6% vs. 7.1%• Increase in serum creatinine levels ≥0.5mg/dL: 7% vs 4%
Approval Date Indications Spectrum of Activity Dosing Clinical Pearls
June 2018 cUTI ESBL, CRE, MRSA 15mg/kg IV daily - Same adverse reactions seen with other aminoglycosides
Wagenlehner FME, et al. N Engl J Med. 2019 Feb 21;380(8):729-740.
47
Eravacycline (XeravaTM)
• Phase 3 study compared eravacycline vs. meropenem • Clinical cure rates at TOC: 90.8% vs. 91.2%• Clinical cure rates in modified-ITT: 92.4% vs. 91.6%• Clinical cure rates in clinically evaluable population: 96.9% vs. 96.1%• Clinical cure in patients with ESBL-producing Enterobacteriaceae: 87.5%
(14/16) vs. 84.6% (11/13)
Approval Date Indications Spectrum of Activity Dosing Clinical Pearls
August 2018 cIAI MRSA, VRE, ESBL, CRE, A. baumannii
1mg/kg IV q12h - Same adverse reactions seen with other tetracyclines
Solomkin JS, et al. Clin Infect Dis. 2018 Dec 18. doi: 10.1093/cid/ciy1029. [Epub ahead of print]
48
10/18/19
25
Omadacycline (NuzyraTM)
• Two phase 3 studies compared omadacycline vs. linezolid• Oasis-1: initiated on IV with option to transition to PO after day 3
• Modified-ITT early clinical response: 84.8% vs. 85.5%• Oasis-2: PO only study
• Modified-ITT early clinical response: 88% vs. 83%• Gastrointestinal adverse events were most common
Approval Date Indications Spectrum of Activity Dosing Clinical Pearls
October 2018 CABP, ABSSSI
MRSA, VRE, ESBL, ±CRE, A. baumannii
LD then 100mg IV or 300mg PO daily
- Same adverse reactions seen with other tetracyclines
O’Riordan W, et al. Lancet Infect Dis. 2019 Aug 29. pii: S1473-3099(19)30275-0.O’Riordan W, et al. N Engl J Med. 2019 Feb 7;380(6):528-538.
49
Imipenem/cilastatin/relebactam (RecarbrioTM)
• Phase 3 study compared imipenem/cilastatin/relebactam vs. colistin + imipenem/cilastatin for HAP/VAP, cIAI, or cUTI due to imipenem non-susceptible pathogens• Favorable overall response: 71% vs. 70%• Day 28 clinical response: 71% vs. 40%• 28-day mortality: 10% vs. 30%• Serious adverse events: 10% vs. 31%; drug-related: 16% vs. 31%
Approval Date Indications Spectrum of Activity Dosing Clinical Pearls
July 2019 cUTI, cIAI ESBL, CRE, P. aeruginosa
1.25g (500 / 500 / 250mg) IV q6h
- Similar adverse effect profile as imipenem/cilastatin
Motsch J, et al. Clin Infect Dis. 2019 Aug 10. pii: ciz530. doi: 10.1093/cid/ciz530. [Epub ahead of print]
50
10/18/19
26
Lefamulin (XenletaTM)
• LEAP-1: 7 days of IV to PO lefamulin vs. moxifloxacin (±) linezolid for moderate-severe CABP• Early clinical response: 87.3% vs. 90.2%• Modified-ITT clinical response: 81.7% vs. 84.2%• Clinically evaluable: 86.9% vs. 89.4%
• LEAP-2: 5 days of PO lefamulin vs. 7 days of moxifloxacin for moderate CABP• Similar results were found
Approval Date Indications Spectrum of Activity Dosing Clinical Pearls
August 2019 CABP MRSA, VRE, Atypicals, MDR-N. gonorrhoeae
150mg IV BID or 600mg PO BID
- First pleuromutilin systemically- Potential for QTc prolongation and fetal harm
File T MJr, et al. Clin Infect Dis. 2019 Feb 4. doi: 10.1093/cid/ciz090. [Epub ahead of print]
51
Summary of Approved AntibioticsMRSA VRE ESBL CRE CR-
PseudomonasMDR-
Acinetobacter
Delafloxacin
Meropenem / vaborbactam
Plazomicin
Eravacycline
Omadacycline
Imipenem / relebactam
Lefamulin
Great activityModerate activityLow/no activity
52
10/18/19
27
Cefiderocol
• Siderophore cephalosporin• Enhanced stability to β-lactamases (AmpC, ESBL, carbapenemases)
• Currently being studied in phase 3 trials as 2g IV q8h as 3-hr infusion• Spectrum of activity is mainly targeted against gram-negatives
• ESBL, CRE, MDR-A. baumannii, MDR-P. aeruginosa, S. maltophilia
• Phase 2 study compared cefiderocol vs. imipenem/cilastatin for cUTI• Clinical response and microbiological response at TOC: 73% vs. 55%• Adverse events: 41% vs. 51% with gastrointestinal being the most common
Portsmouth S, et al. Lancet Infect Dis. 2018 Dec;18(12):1319-1328.
53
Iclaprim
• Dihydrofolate reductase inhibitor • Designed to overcome trimethoprim resistance without sulphonamide use
• Spectrum of activity is mainly targeted against gram-positives• MRSA, vancomycin-resistant strains
• Two phase 3 trials were conducted (REVIVE-1 and REVIVE-2) comparing iclaprim vs. vancomycin for ABSSSI• ≥20% reduction in lesion size: 79.6% vs. 78.8%• Adverse reactions were same except for ↑ incidence of SCr with vancomycin
• FDA requested additional data to evaluate risk for liver toxicity
Huang DB, et al. Int J Antimicrob Agents. 2018 Aug;52(2):233-240.
54
10/18/19
28
Zoliflodacin
• Spiropyrimidinetrione against bacterial type II topoisomerases• FDA awarded fast track status as PO option for gonococcal infections• Phase 2 study compared zoliflodacin 2g or 3g PO x1 dose vs.
ceftriaxone 500mg IM x1 dose for uncomplicated or untreated urogenital gonorrhea• Microbiologic cure in the micro-ITT: 96% vs. 96% vs. 100%• All rectal patients were cured in all 3 groups• Pharyngeal infections: 50% vs. 82% vs. 100%• Most adverse reactions with zoliflodacin were gastrointestinal
Taylor SN, et al. N Engl J Med. 2018 Nov 8;379(19):1835-1845.
55
Ridinilazole
• Demonstrates rapid bactericidal activity for C. difficile infection (CDI) • Diminish production of C. difficile toxins
• Preclinical studies show negligible systemic exposure• Phase 2 study compared ridinilazole vs. vancomycin x 10 days
• Sustained clinical response: 66.7% vs. 42.4%, showing superiority• Largely due to reduced CDI 30-day recurrence rates
• Adverse effect profile was similar to vancomycin, most being gastrointestinal
• Lower propensity for collateral damage to gut microbiome compared with vancomycin
Vickers RJ, et al. Lancet Infect Dis. 2017 Jul;17(7):735-744.
56
10/18/19
29
Fosfomycin
• Works against many gram-positive and gram-negatives• MRSA, VRE, ESBL, CRE• Does not work against Pseudomonas and Acinetobacter sp.
• Phase 2/3 study evaluated IV fosfomycin vs. piperacillin/tazobactam for treatment of cUTI• Overall success: 64.7% vs. 54.5%• Clinical cure at TOC: 90.8% vs. 91.6%• Adverse reactions include hypokalemia, hypernatremia, ↑ AST/ALT
• FDA rejected approval due to manufacturing issues
Kaye KS, et al. Clin Infect Dis. 2019 Mar 6. pii: ciz181. doi: 10.1093/cid/ciz181. [Epub ahead of print]
57
New and Future Antibiotics in the Pipeline
Jonathan Cho, PharmD, MBA, BCIDP, BCPS
Clinical Associate ProfessorThe University of Texas at Tyler Fisch College of Pharmacy
58
10/18/19
30
Q&A Session 1 – 15 min
Moderated by Dr. Milito
1. Bugs & Drugs for the Older Adult—Spencer Durham2. Antibiotic Adverse Drug Events: Improving Patient Assessment and
Management—Joshua Chou3. New and Future Antibiotics in the Pipeline—Jonathan Cho
Please logon to: www.ascp.com/qa and find the session title to submit your questions.
59
60
10/18/19
31
Golden Nuggets: Bugs, Drugs and Antibiotic Stewardship:
2nd Hour
61
Optimizing The Use of Clinical Laboratory Values in Antimicrobial Stewardship
Nicholas Ladikos, PharmD, BCPS, BCGP, BCIDPClinical Coordinator
Antimicrobial Stewardship Program Lead PharmacistInvestigational Drug Program Lead PharmacistJohns Hopkins Medicine | Suburban Hospital
62
10/18/19
32
Speaker Information–Bio• Committee member for ASCP,
SIDP, ACCP, SHEA, and MSHP• Additional degrees in
Biochemistry, Finance, and International Business
• LEAN/Six Sigma Certification• Recipient of The Johns Hopkins
Patient Safety Award (twice)
63
Disclosure – Nicholas Ladikos, PharmDBCPS, BCGP, BCIDP• I have no actual or potentially relevant financial relationship to
disclose and no conflict of interest in relation to this activity
64
10/18/19
33
Learning Objectives
At the end of this presentation, attendees will be able to understand:
• The effects of immunosenescence on laboratory values• The complexities of penicillin allergy skin testing and procalcitonin
values• The limitations of current clinical laboratory instrumentation
65
Historical Context: Hippocrates (c. 425 BC)
• Separated medicine from superstition and religion and made it a science• The original uroscopist:
Advocated examination of urine to diagnose disease• “Understand the patient as an
individual”
66
10/18/19
34
Clinical Laboratory Values
• 13 billion tests performed annually in the U.S.• Acute (baseline) and chronic changes (trends)• Initiate medication regimens, then adjust based on new information• Order tests only when necessary
• Will you take action on the results?
67
Is a Laboratory Value “WNL” Really Normal?
• Population norms can be established for any physiologic parameter and its laboratory measurement
•Normal lab value = Mean ± 2 SD of healthy people
-i.e., 95% of results
•Thus, 5% of results are classified as "abnormal," even though they represent variability within a normal population
68
10/18/19
35
Immunosenescence
• Multifactorial, progressive decline in immune function with increasing age• Low-grade chronic inflammation
(“inflamm-aging”)• Increased incidence and severity
of infections• Attenuates the host’s capacity to
respond to infections• Difference in clinical presentation
of infections
Infe
ctio
nSC
r/GFR
/CrC
l
ESR
Bloo
d Gl
ucos
eFe
ver/
Chills
?
69
“All that is gold does not glitter, not all who wander are lost, and not all laboratory values are legitimate.”
Clinical Suspicion
Bacterial infection
Aspergillosis
Syphilis
Instrument False Positive/False Negative
Sample contamination or inadequate smear preparation
False-positive if concomitant piperacillin-tazobactam
False-positive screen in patients with lupus
70
10/18/19
36
Microbiology Laboratory—Your [New] BFF!
• Institutional/Facility antibiograms• Feeder hospital’s antibiograms
• Rapid/POC tests• Turnaround time from preliminary/final cultures and susceptibilities
to regimen change• Strategic suppression and/or displaying of susceptibilities
71
Medical Team: “Patient is fine, but the urine…”Urinalysis in Asymptomatic Bacteriuria (ASB)
Screen/Treat• Patients undergoing endo-urologic surgery
(1 or 2 doses)• Renal transplant patients within one
month of transplant• Pregnant women (4-7 days)
Do NOT Screen/Treat• Elderly persons living independently or in
a long-term care facility• Patients with indwelling urinary catheters
of any duration• Patients with diabetes• Patients with spinal cord injury• Healthy non-pregnant women of any age
72
10/18/19
37
Patient: “I’m Allergic to Penicillin…”
• ~10% of US population self-identifies as allergic to penicillin• <0.05%-1% have an IgE-mediated penicillin allergy
• 1/100,000 experience anaphylaxis
• 1%-2% cross-allergy to carbapenems/select cephalosporins
• Do your due diligence—Investigate, interpret, ask questions!• Beta-lactams often first-line therapy• Penicillin allergy skin testing (NPV ~98%)
73
Which is the Penicillin Allergy?
74
10/18/19
38
Procalcitonin
The Good…• Serum biomarker that rises in
response to bacterial infections• Approved for CAP and sepsis
• Bacterial versus viral/atypical• 95% NPV
• Known kinetics (follow trends)
The Bad…• Not for viral/atypical infections• Many other causes of systemic
inflammation• Not perfect
75
The Future…
• Cell-free DNA• 16s (bacteria)• 18s (fungi)
76
10/18/19
39
Self-Assessment Question
Which of the following is true?
A. The normal value for a laboratory measurement is usually defined as its mean value ± 3 SD.
B. Infections manifest with typical signs or symptoms characterizing disease the same for adults of all ages.
C. ~1% of the U.S. population self-identifies as having an allergy to penicillin.
D. Patients with indwelling catheters should always be treated with antibiotics.
E. Hippocrates advocated to understand the patient as an individual.
77
Self-Assessment Question
Which of the following is true?
A. The normal value for a laboratory measurement is usually defined as its mean value ± 3 SD.
B. Infections manifest with typical signs or symptoms characterizing disease the same for adults of all ages.
C. ~1% of the U.S. population self-identifies as having an allergy to penicillin.
D. Patients with indwelling catheters should always be treated with antibiotics.
E. Hippocrates advocated to understand the patient as an individual.
78
10/18/19
40
Golden Nuggets
• Don’t interpret the patient based on the test• Interpret the test based on the patient
• Understand the limitations and timing of tests• Partner with your clinical laboratory staff and other infection
prevention specialists!
79
Optimizing The Use of Clinical Laboratory Values in Antimicrobial Stewardship
Nicholas LadikosPharmD, BCPS, BCGP, BCIDP
Thank you!
80
10/18/19
41
Clostridioides difficile Infection in the Older Adult
Elias B. Chahine, PharmD, FCCP, FFSHP, BCPS, BCIDPProfessor of Pharmacy Practice
Gregory School of PharmacyPalm Beach Atlantic University
81
Conflicts of Interest
• Speakers’ bureau of Merck & Co, Inc.• Speaker’s bureau of Paratek Pharmaceuticals, Inc.
82
10/18/19
42
Outline
• Epidemiology
• Clinical presentation
• Risk factors
• Treatment
• Prevention
https://www.cdc.gov/cdiff/what-is.html
83
Epidemiology
Leffler DA. N Engl J Med. 2015;372:1539-48
84
10/18/19
43
Epidemiology
www.cdc.gov/vitalsigns/HAI/index.html
85
Epidemiology
Chopra T et al. Pharmacotherapy. 2016;36:1281-9
86
10/18/19
44
Epidemiology
Clements AC et al. Lancet Infect Dis. 2010;10:395-404
87
Question
•Which statement is true?
• A) CDI cases are decreasing in frequency and severity.
• B) C. difficile is more likely to cause disease in children than older adults.
• C) More than 50% of healthy adults are carriers of C. difficile in their stool.
• D) The NAP1/BI/027 and 078 ribotypes of C. difficile are very virulent.
88
10/18/19
45
Clinical Presentation• Asymptomatic carrier
• Offensive-smelling acute watery diarrhea and fever
• Pseudomembranous colitis with adherent plaques
• Toxic megacolon and systemic toxicity
• Fulminant colitis, sepsis, and paralytic ileus
• Recurrent infections
Grace E et al. Sr Care Pharm. 2019;34:29-42
89
Clinical Presentation
Definitions Supportive data
Initial episode, non-severe WBC count <15,000 cells/mLAND
SCr <1.5 mg/dL
Initial episode, severe WBC count ≥15,000 cells/mLOR
SCr ≥1.5 mg/dL
Initial episode, fulminant Hypotension or shock, ileus, megacolon
McDonald LC et al. Clin Infect Dis. 2018;31:431-55
90
10/18/19
46
Question
• Which patient would be classified under the category of severe infection according to the IDSA/SHEA guidelines?
• A) A 65-year-old man with a WBC count of 10,100 cells/mL and a SCr of 1.1 mg/dL
• B) A 70-year-old man with a WBC count of 12,200 cells/mL and a SCr of 1.2 mg/dL
• C) A 75-year-old woman with a WBC count of 16,300 cells/mL and a SCr of 1.6 mg/dL
• D) A 79-year-old woman with a WBC count of 10,000 cells/mL and a SCr of 1.4 mg/dL
91
Risk Factors• Drug-induced:
• Antibiotic exposure
• Broad-spectrum antibiotics
• Multiple antibiotics
• Long-term antibiotics
• Proton pump inhibitors
• Histamine-2 receptor blockers
• Chemotherapy agents
• Non drug-induced:
• Advanced age
• Female gender
• Caucasian ethnicity
• Severe underlying disease
• Immunocompromising conditions
• Manipulation of the GI tract
• Hospitalization or ICU admission
Grace E et al. Sr Care Pharm. 2019;34:29-42
92
10/18/19
47
Risk Factors
Low risk Medium risk High risk
Aminoglycosides Penicillins Clindamycin
Tetracyclines Trimethoprim/ sulfamethoxazole
Ampicillin
Rifampin Macrolides Amoxicillin
Metronidazole Cephalosporins
Vancomycin Fluoroquinolones
Leffler DA. N Engl J Med. 2015;372:1539-48
93
Question
•Which antibiotic is the LEAST likely to cause CDI?
• A) Ampicillin
• B) Ceftriaxone
• C) Gentamicin
• D) Levofloxacin
94
10/18/19
48
Treatment
• Stop offending antibiotics when possible
• Replace fluid and electrolytes
• Avoid antimotility agents
• Consider surgical interventions in severe cases
• Treat for 10 days
McDonald LC et al. Clin Infect Dis. 2018;31:431-55
95
TreatmentDefinitions Supportive data Recommended treatment
Initial episode, non-severe
WBC <15,000 cells/mLANDSCr <1.5 mg/dL
Vancomycin 125 mg PO every 6 hrs for 10 daysFidaxomicin 200 mg PO every 12 hrs for 10 daysMetronidazole 500 mg PO every 8 hrs for days if no access to first-line options
Initial episode, severe WBC ≥15,000 cells/mLORSCr ≥1.5 mg/dL
Vancomycin 125 mg PO every 6 hrs for 10 daysFidaxomicin 200 mg PO every 12 hrs for 10 days
Initial episode, fulminant
Hypotension or shock, ileus, megacolon
Vancomycin 500 mg PO/NG every 6 hrs+ Metronidazole 500 mg IV every 8 hrs± Vancomycin via rectal instillation
McDonald LC et al. Clin Infect Dis. 2018;31:431-55
96
10/18/19
49
TreatmentDefinitions Recommended treatment
First recurrence Vancomycin 125 mg PO every 6 hrs for 10 days if metronidazole was used initiallyVancomycin 125 mg PO every 6 hrs for 10 to 14 days, every 12 hrs for a week, every 24 hrs for a week, and then every 2 or 3 days for 2 to 8 weeks (tapered and pulsed regimen)Fidaxomicin 200 mg PO every 12 hours for 10 days if vancomycin was used initially
Second or subsequent recurrence
Vancomycin 125 mg PO every 6 hrs for 10 to 14 days, every 12 hrs for a week, every 24 hrs for a week, and then every 2 or 3 days for 2 to 8 weeks (tapered and pulsed regimen)Vancomycin 125 mg PO every 6 hrs for 10 days followed by rifaximin 400 mg PO every 8 hours for 20 days (rifaximin chaser)Fidaxomicin 200 mg PO every 12 hours for 10 daysFecal microbiota transplantation
McDonald LC et al. Clin Infect Dis. 2018;31:431-55
97
Bezlotoxumab
Wilcox MH et al. N Engl J Med. 2017;376:305-17
98
10/18/19
50
Case Vignette
• M.F., a 71-year-old man, was transferred from the nursing home to the hospital for the management of HAP. • He is receiving cefepime and ciprofloxacin.• On day 8, his lungs are clear, and he is no longer complaining of
shortness of breath.• However, he is now complaining of foul-smelling diarrhea and is
diagnosed with CDI.• WBC 22,000 cells/mm3; SCr 2 mg/dL; Alb 2.4 g/dL. • All: penicillin (itching).
99
Question
• What is the best recommendation for M.F.?
• A) Start vancomycin 125 mg PO every 6 hours and continue cefepime and ciprofloxacin
• B) Start vancomycin 125 mg PO every 6 hours and discontinue cefepime and ciprofloxacin
• C) Start vancomycin 1000 mg IV every 12 hours and continue cefepime and ciprofloxacin
• D) Start vancomycin 1000 mg IV every 12 hours and discontinue cefepime and ciprofloxacin
100
10/18/19
51
Prevention
• Implement institution-based infection control programs
• Isolate affected patients in single rooms
• Use barrier precautions such as gloves and gowns
• Emphasize hygiene particularly hand washing
• Implement antimicrobial stewardship programs
• Discontinue unnecessary gastric acid suppression
Marshall LL et al. Consult Pharm. 2017;32:24-41
101
Key References and Readings
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America. Clin Infect Dis. 2018;66:987-994.
• Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539-48.
• Grace E, Chahine EB. Updates on Clostridioides (Clostridium) difficileinfection with emphasis on long-term care. Sr Care Pharm. 2019;34:29-42.
102
10/18/19
52
Clostridioides difficile Infection in the Older Adult
Elias B. Chahine, PharmD, FCCP, FFSHP, BCPS, BCIDPProfessor of Pharmacy Practice
Gregory School of PharmacyPalm Beach Atlantic University
103
Multi-Drug Resistant Organisms
Eddie Grace, Pharm.D., BCIDP, AAHIVP, FIDSA
President & Chief Infectious Diseases Consultant Sovereign Medical Consulting, LLC
104
10/18/19
53
Speaker Information –Bio
• Board-Certified Infectious Diseases Pharmacist • Fellow of the Infectious Diseases Society of America (IDSA)• American Academy of HIV Medicine Certified HIV
Pharmacist • ASCP Antimicrobial Stewardship and Infection Control
Committee • Current Chair of ACCP HIV PRN (2018-19)
105
Disclosure – Eddie Grace, Pharm.D., BCIDP, AAHIVP, FIDSA• None to disclose
106
10/18/19
54
Gram-negative MDROsEvolution of Resistance • Extended-Spectrum Beta-Lactamase (ESBL):
• Enzymes able to hydrolyze third and fourth generation cephalosporins and monobactams.
• Inhibited by CLA, TZB, and SLB• Resistance genes acquired through plasmids (not chromosomally present)
• Carbapenem-Resistant Enterobacteriaceae (CRE)/ Carbapenemase Producing Enterobacteriaceae (CPE)• Enzymes able to hydrolyze penicillins, cephalosporins, most ß-lactams, most
ß-lactamase inhibitors (±TZB), and carbapenems
J of Chemother 2017;29(S1): 2-9
107
Gram-Negative MDROsEvolution of Resistance
1940s 1950s 1960s 1970s 1980s 1990s 2000-2010 2010-Now
1941: Penicillin
introduced
1940: Penicillinase Identified in E. coli
1965: TEM-1 Identified in
E. coli
1976: ß-lactamase inhibitors
introduced
1981: 3rd
Generation Cephalosporins
introduced
1983: SHV-2 Identified First ESBL
1985: Imipenem introduced
1989: ampC(CMY-1) & ESBL (CTX-
M) identified
1991: CRE identified(MBL and
OXA-1)
2001: KPC-1 identified
(NC, USA)
1968: SHV-1 Identified
J of Chemother 2017;29(S1): 2-9J Basic Microbiol 2017;57:460-70Infect Dis Clin N Am 2016:30:347-75Annu Rev Microbiol 2011;65:455-78
108
10/18/19
55
Gram-Negative MDROsEvolution of Resistance
Infect Dis Clin N Am 2016;30:347-75Annu Rev Microbiol 2011;65:455-78
• CTX-M has become the dominant ESBL with a prevalence of 35-45% of all E. coli related UTIs and BSIs
• Currently >5 subtypes have been identified • E. coli CTX-M has been identified as E. coli Sequence Type 131 (ST131)• Also known as phylogenetic type B2 or serotype 025:H4• Resistance to CLA and TZB• Resistance to fluoroquinolones (especially ciprofloxacin) is common • Co-resistance to aminoglycosides and TMP/SMX also common
109
Gram-negative MDROs Evolution of Resistance
J Basic Microbiol 2017;57:460-70
110
10/18/19
56
Gram-negative MDROs Evolution of Resistance
J of Chemother 2017;29(S1): 2-9
111
Gram-Negative MDROsE. coli • Gram-negative rod• Facultative anaerobe• Lactose and D-glucose fermenter• Member of the Enterobacteriaceae family • Most common organism in the small intestines• Wild-type E. coli is typically susceptible to most antibiotic classes:
• penicillins, aminopenicillins, cephalosporins, fluoroquinolones, sulfonamides, carbapenems, aminoglycosides, nitrofurantoin, fosfomycin, ß-lactam/ß-lactamase inhibitors
Curr Opin Infect Dis 2010;23:320-6Infect Dis Clin N Am 2016;30:347-75
112
10/18/19
57
MDRO E. coli Colonization in NH-patients (42.6%)
E. coli resistant antibiotics Prevalence among E. coli ST131 isolates
3-drug resistance (88.4% of all MDRO E. coli)
Ciprofloxacin, extended-spectrum penicillins, and gentamicin
74.4% of all
Ciprofloxacin, extended spectrum penicillin, and extended-spectrum cephalosporins
23.2%
4-drug resistance (10.5% of all MDRO E. coli)
Ciprofloxacin, extended-spectrum penicillins, extended-spectrum cephalosporins, and gentamicin
100%
Gram-negative MDROs E. Coli –Resistance
Infect Control Hosp Epidemiol 2015;36(8):930-935
113
Gram-negative MDROs E. Coli –Resistance • E. coli resistance patterns:
• ESBL E. coli • Resistance to one or more of the following:
• Penicillins • Cephalosporins • ß-lactam ß-lactamase inhibitor combinations• Fluoroquinolones • Aminoglycosides • TMP/SMX• Monobactams • Carbapenems (≥1 agent)
• CR-E. coli• Resistance to all the following:
• Carbapenems (ALL)• Cephalosporins (ALL)
Emerg Infect Dis 2015;21(9):1611-16Infect Dis Clin N Am 2016;30:347-75
114
10/18/19
58
Gram-negative MDROs E. Coli –CipREc• Ciprofloxacin-Resistant E. coli (CipREc)
• 2011 study 34% of NH-residents colonized with CipREc• Risk factor for colonization was use of medical devices (HR 1.93)
• 2014 study showed a prevalence among colonized NH-residents of 47.5% (57 of 120)• Time to colonization positive averaged 46 days (IQR 21-296 days)• Risk factors for CR-EC acquisition included:
• Fecal incontinence (HR 1.78, 95%CI 1.04-3.06, p=0.04)• Amoxicillin-clavulanate receipt within 12-months (HR 6.48, 95%CI 1.43-29.4, p=0.02)• Urinary catheter use (HR 3.81, 95%CI 1.06-13.8, p=0.04)
Infect Control Hosp Epidemiol 2011;32:177-80J Infect Dis 2014;209:420-425
115
Gram-negative MDROs E. Coli –CipREc• 2016 study in high-risk NH-residents (urinary-catheter or enteral
nutrition tubes or both)• 15% of all NH-residents were colonized with CipREc with an increase of
7.7%/year • 62.2% of CipREc were identified as ST131 (ESBL+)• All residents with CipREc had urinary-catheters• 63.2% of non-colonized residents had urinary-catheters
• Risk of CipREc was higher with suprapubic-catheter vs ureteral- catheters (22.6% vs 12.3%, respectively)
• Interestingly, residents with enteral nutrition tubes were less likely to have CipREc colonization (28.3% vs 49.2%)
Infect Control Hosp Epidemiol 2016;37(4):440-447
116
10/18/19
59
Gram-negative MDROs E. Coli –ESBL/ST131• Nosocomial colonization rate in the US:
• 7.8% in 2010 and 18.3% in 2014
• In NH-residents the mean ESBL colonization rate is ~17% (data from 2016) with a range from 8-28%• Risk factors for colonization:
• MDRO history (OR 4.1, 95%CI 1.6-10.4, p=0.003)• Bed-bound status (OR 2.6, 95%CI 1.3-5.4, p=0.008)• Urinary/fecal incontinence (OR 8.86, p<0.001)• Presence of urinary catheter (OR 8.57, P<0.001)
Infect Gen Evol 2018;61:185-8Med Sci Monit 2013;19:317-326
117
Gram-negative MDROs E. Coli –ESBL/ST131• NH-residents are at increased risk of E.coli ST131 infections and
resulting bacteremia • 2014 study showed that being a resident of a LTCF increased the risk of
hospital-onset ESBL bacteremia by 5.1-fold (95%CI 2.2-11.9, p<0.01) in residents without antibiotic use in the past 30 days and without history of ESBL • Odds ratio increased to 6.9 with antibiotic use in prior 30 days• Odds ratio increased by 1.8 if resident had history of ESBL infections (95%CI 1.3-2.7,
p<0.01)• The risk remained elevated even after 48-hours of hospitalization (OR 3.4, 95%CI 1.3-9.0,
p=0.01)
Infect Control Hosp Epidemiol 2014;35(5):519-26
118
10/18/19
60
Gram-negative MDROs ESBL E. Coli –Treatment
Antibiotic/Class Place in therapy Indications Comments
Carbapenems Drugs of choice All Consider Etrapenem when pseudomonas and Acinetobacter not suspected Consider extended infusions
Piperacillin-tazobactam Alternative All Debatable whether it should be used in ESBL + infections. Latest study in 2018 supports its use
Fosfomycin Alternative UTI (mild-moderate High resistance threshold to ESBLs but use based on C&S results
Nitrofurantoin Alternative UTI (mild-moderate)
Infect Dis Clin N Am 2016;30:347-75
Polymyxin E/B Drugs of choice for severe infections with evidence of resistance to carbapenems
All Use in combination with other agents (never use monotherapy)
Aminoglycosides Alternative UTI Can be used in the treatment of UTIs is shown susceptible. Do not use monotherapy for severe invasive infections
Cephalosporins AVOID High likelihood of resistance
Fluoroquinolones AVOID
TMP/SMX AVOID
119
• Carbapenem-Resistant Enterobacteriaceae are resistant to carbapenems and most other antibiotic classes previous mentioned • CRE are encoded by one or more of the following genes: NDM, OXA, VIM,
and IMP• 4.6% of NH-residents admitted to hospitals are colonized with a
carbapenem-resistant GN• Approximately 25% are colonized with CR-E. coli
• CRE (including E. coli) infections account for 4.2% of all infections in the US (2011)• Increase from 1.2% of infections in 2001
• E. coli accounts for 10% of all CRE-related infections
Gram-negative MDROs E. Coli –CRE
Emerg Infect Dis 2015;21(9):1611-1616Am J Infect Control 2016;44:126-30
120
10/18/19
61
Self-Assessment Question
Which of the following antibiotics would be considered an appropriate agent for the empiric treatment of a suspected ESBL E. coli (ST131) bacteremia secondary to a UTI of the same organism?
A. Tobramycin B. Colistin C. ErtapenemD. Levofloxacin
121
Self-Assessment Question
Which of the following antibiotics would be considered an appropriate agent for the empiric treatment of a suspected ESBL E. coli (ST131) bacteremia secondary to a UTI of the same organism?
A. Tobramycin B. Colistin C. ErtapenemD. Levofloxacin
122
10/18/19
62
References• Han JH, Maslow J, Han X, et al. Risk factors for the development of gastrointestinal colonization with
fluoroquinolone-resistant Escherichia coli in residents of long-term care facilities. J Infect Dis. 2014 Feb 1;209(3):420-5.
• Dommeti P, Wang L, Flannery EL, et al. Patterns of ciprofloxacin-resistant gram-negative bacteria colonization in nursing home residents. Infect Control Hosp Epidemiol. 2011 Feb;32(2):177-80.
• Chong Y, Shimoda S, Shimono N. Current epidemiology, genetic evolution and clinical impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Genet Evol. 2018 Jul;61:185-188
• Pobiega M, Wojkowska-Mach J, Chmielarczyk A, et al. Molecular characterization and drug resistance of Escherichia coli strains isolated from urine from long-term care facility residents in Cracow, Poland. Med Sci Monit. 2013 May 1;19:317-26.
• Venkatachalam I, Yang HL, Fisher D, et al. Multidrug-resistant gram-negative bloodstream infections among residents of long-term care facilities. Infect Control Hosp Epidemiol. 2014 May;35(5):519-26
• Cunha CB, Kassakian SZ, Chan T, et al. Screening of nursing home residents for colonization with carbapenem-resistant Enterobacteriaceae admitted to acute care hospitals: Incidence and risk factors. Am J Infect Control. 2016 Feb;44(2):126-30
123
References• Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a
review. J Chemother. 2017 Dec;29(sup1):2-9• Adler A, Katz DE, Marchaim D. The Continuing Plague of Extended-spectrum β-lactamase-producing
Enterobacteriaceae Infections. Infect Dis Clin North Am. 2016 Jun;30(2):347-375• Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases
from gram-negative bacteria. Annu Rev Microbiol. 2011;65:455-78• Padmini N, Ajilda AAK, Sivakumar N,et al. Extended spectrum β-lactamase producing Escherichia coli and
Klebsiella pneumoniae: critical tools for antibiotic resistance pattern. J Basic Microbiol. 2017 Jun;57(6):460-470.• Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing
epidemiology and clinical impact. Curr Opin Infect Dis. 2010 Aug;23(4):320-6.• D'Agata EM, Habtemariam D, Mitchell S. Multidrug-Resistant Gram-Negative Bacteria: Inter- and
Intradissemination Among Nursing Homes of Residents With Advanced Dementia. Infect Control Hosp Epidemiol. 2015 Aug;36(8):930-5
• Chea N, Bulens SN, Kongphet T, et al. Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae. Emerg Infect Dis. 2015 Sep;21(9):1611-6
124
10/18/19
63
Multi-Drug Resistant Organisms
Eddie Grace, Pharm.D., BCIDP, AAHIVP, FIDSA
President & Chief Infectious Diseases Consultant Sovereign Medical Consulting, LLC
125
Q&A Session 2 – 15 min
Moderated by Dr. Milito
4. OpNmizing The Use Of Clinical Laboratory Values In AnNmicrobial Stewardship—Nicholas Ladikos
5. Clostridioides difficile InfecNon in the Older Adult—Elias B. Chahine 6. MulN-Drug Resistant Organisms—Eddie Grace
Please logon to: www.ascp.com/qa and find the session title to submit your questions.
126
10/18/19
64
127
Golden Nuggets: Bugs, Drugs and Antibiotic Stewardship
128